| Literature DB >> 25866538 |
Hui Qiang1, Huitong Liu2, Ming Ling1, Kunzheng Wang3, Chen Zhang3.
Abstract
Background. This study was aimed at investigating the pathogenesis of oxidative stress in steroid-induced avascular necrosis of the femoral head (SANFH) and at exploring the mechanism and protective effects of Panax notoginseng saponins (PNS) on early SANFH. Methods. 80 adult New Zealand rabbits were randomly divided into control group, model group, and PNS group. In model group, equine serum was injected into auricular vein; then methylprednisolone was injected into gluteus. In PNS group, PNS was applied for 14 consecutive days before methylprednisolone management. At different time points, serum and femoral heads were prepared for T-AOC, SOD, GSH-PX, ·OH, and MDA determination. Two weeks after steroid management, all femoral heads were assessed with MRI and HE staining. Results. Typical early osteonecrosis symptoms were observed in model group. Our results showed that PNS could significantly ameliorate the decrease of T-AOC level, improve SOD and GSH-PX activity, suppress ·OH ability, and augment MDA level. Besides, PNS improved MRI and pathological changes of the femoral head, markedly reducing the incidence of osteonecrosis. Conclusion. Based on our research, we found oxidative stress played a positive role in the occurrence of SANFH where reactive oxygen species was the direct cause. PNS could protect rabbits against early steroid-induced osteonecrosis of femoral head by its antioxidative effect.Entities:
Year: 2015 PMID: 25866538 PMCID: PMC4378605 DOI: 10.1155/2015/719370
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1MRI imaging of bilateral femoral heads of rabbits in the control group.
Figure 2MRI imaging of bilateral femoral heads of rabbits in the model group.
Figure 3MRI imaging of bilateral femoral heads of rabbits in the PNS group.
Figure 4Outlook of rabbit femoral heads in the three groups.
Figure 5Results of HE staining of the femoral heads in the three groups (×200).
Serum T-AOC results of the three groups (u/mL).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 8.04 ± 0.71 | 8.17 ± 0.76 | 8.09 ± 0.75 | 8.21 ± 0.79 | 8.15 ± 0.69 |
| Model | 7.36 ± 0.47 | 6.32 ± 0.45** | 6.01 ± 0.42** | 5.81 ± 0.41** | 7.03 ± 0.39** |
| PNS | 7.34 ± 0.41 | 7.12 ± 0.44∗# | 7.01 ± 0.48∗## | 7.23 ± 0.45∗## | 7.78 ± 0.51# |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
Serum SOD activity of the three groups (u/mL).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 250.36 ± 21.13 | 248.21 ± 19.37 | 252.36 ± 24.18 | 245.73 ± 20.74 | 247.04 ± 18.97 |
| Model | 235.12 ± 19.71 | 201.24 ± 14.78** | 196.21 ± 15.73** | 192.67 ± 14.21** | 209.54 ± 17.12** |
| PNS | 232.69 ± 21.61 | 220.41 ± 15.02* | 215.19 ± 16.12* | 219.34 ± 18.86∗# | 231.17 ± 20.69# |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05.
Serum GSH-PX activity of the three groups (u/mL).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 331.04 ± 21.35 | 334.16 ± 23.92 | 332.87 ± 20.36 | 329.38 ± 21.69 | 332.29 ± 19.68 |
| Model | 320.29 ± 19.18 | 289.54 ± 16.75** | 282.34 ± 16.15** | 276.91 ± 15.17** | 305.62 ± 16.89* |
| PNS | 324.93 ± 20.47 | 295.23 ± 17.82** | 296.28 ± 16.62∗∗# | 298.21 ± 18.42∗# | 318.19 ± 17.12# |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05.
Serum inhibition of ·OH of the three groups (u/mL).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 551.56 ± 41.54 | 540.58 ± 42.79 | 546.56 ± 45.51 | 551.68 ± 47.21 | 549.23 ± 39.19 |
| Model | 526.16 ± 35.63 | 441.23 ± 28.67** | 436.23 ± 29.82** | 424.43 ± 23.65** | 478.52 ± 29.64** |
| PNS | 521.92 ± 32.74 | 478.34 ± 35.15∗∗# | 482.37 ± 28.31∗∗# | 502.78 ± 26.97∗## | 527.42 ± 31.58# |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
Serum MDA content in the three groups (nmol/mL).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 4.73 ± 0.67 | 4.51 ± 0.81 | 4.61 ± 0.71 | 4.77 ± 0.91 | 4.52 ± 0.75 |
| Model | 4.78 ± 0.63 | 7.36 ± 1.02** | 7.87 ± 1.52** | 8.93 ± 1.73** | 6.85 ± 0.87** |
| PNS | 4.80 ± 0.57 | 5.97 ± 0.96∗# | 6.47 ± 1.42∗# | 6.12 ± 0.89∗## | 5.14 ± 0.89## |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
T-AOC results in the femoral head of the three groups (u/mg prot).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 1.68 ± 0.21 | 1.73 ± 0.32 | 1.69 ± 0.27 | 1.71 ± 0.19 | 1.70 ± 0.26 |
| Model | 1.63 ± 0.24 | 1.44 ± 0.18* | 1.36 ± 0.18* | 1.12 ± 0.15** | 1.08 ± 0.19** |
| PNS | 1.59 ± 0.25 | 1.51 ± 0.21* | 1.43 ± 0.22* | 1.34 ± 0.14∗∗# | 1.50 ± 0.19∗## |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
SOD activity in the femoral heads of the three groups (u/mg prot).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 38.78 ± 3.25 | 40.23 ± 3.98 | 38.28 ± 3.95 | 39.91 ± 2.25 | 38.07 ± 3.39 |
| Model | 37.62 ± 2.19 | 34.27 ± 2.24** | 32.89 ± 2.14** | 31.69 ± 2.06** | 32.15 ± 1.37** |
| PNS | 36.97 ± 2.78 | 35.69 ± 2.67* | 34.54 ± 2.25* | 36.29 ± 1.98∗## | 35.97 ± 2.06∗## |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
GSH-PX activity in the femoral heads of the three groups (u/mg prot).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 107.24 ± 8.74 | 112.42 ± 10.76 | 109.24 ± 8.46 | 109.96 ± 10.06 | 110.27 ± 9.96 |
| Model | 101.53 ± 9.78 | 86.76 ± 4.26** | 84.26 ± 4.06** | 79.09 ± 4.71** | 60.35 ± 3.74** |
| PNS | 98.37 ± 10.21 | 87.24 ± 5.97* | 89.01 ± 6.02∗# | 95.34 ± 6.86∗## | 94.57 ± 7.01## |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
Inhibition of ·OH in the femoral heads of the three groups (u/mg prot).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 64.27 ± 8.71 | 65.31 ± 9.95 | 64.34 ± 8.91 | 62.78 ± 9.32 | 65.19 ± 9.07 |
| Model | 61.65 ± 9.28 | 47.43 ± 5.14** | 43.16 ± 4.36** | 40.29 ± 5.21** | 41.08 ± 4.79** |
| PNS | 59.78 ± 10.21 | 50.89 ± 5.62** | 49.43 ± 4.75∗∗# | 54.96 ± 5.01∗## | 53.61 ± 6.23∗## |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.
MDA Contents in the femoral heads of the three groups (nmol/mg prot).
| Groups | 0 d | 3 d | 5 d | 7 d | 14 d |
|---|---|---|---|---|---|
| Control | 9.94 ± 0.71 | 10.05 ± 0.76 | 9.79 ± 0.83 | 10.25 ± 0.73 | 10.12 ± 0.89 |
| Model | 10.98 ± 0.67 | 12.87 ± 0.98** | 12.76 ± 0.89** | 13.42 ± 0.76** | 13.16 ± 1.24** |
| PNS | 10.12 ± 0.43 | 11.32 ± 0.74∗# | 11.67 ± 0.71∗# | 11.09 ± 0.69∗## | 11.23 ± 0.87∗# |
*Compared with the control group, P < 0.05; **compared with the control group, P < 0.01; #compared with the model group, P < 0.05; ##compared with the model group, P < 0.01.